$2.77
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Country

DE

CEO

Dr. Christian Wojczewski

IPO date

1999

Employees

4,526

ISIN

DE0005664809

Key stats

Open

$2.85

Volume

14.73K

Market cap

$993.61M

Prev. close

$2.84

Impl / hst vl

-

Open interest

$0.00

$2.75

Day’s Range

$2.85

$2.31

52W Range

$3.87

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
1.17
P/B
1.24
Current ratio
1.68
Debt / Equity
-
ROE
-24.55%
Gross margin
-1.00%
Income growth
-933.81%
FCF growth
-130.56

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$4.08
The top 10 analysts forecasts that 12-month price may increase by 47.12%, with a low of $2.56 and a high of $5.92
$2.56
Low
$4.08
Avg
$5.92
High
Current price

Earnings

Q1 ‘26 revenue
$179.08M
Q1 ‘26 net income
-$139.40M
Revenue
Net income
Previous EPS
-$0.79
Estimate EPS
-$0.33
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply